196 related articles for article (PubMed ID: 26169213)
1. Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.
Romero-Laorden N; Doger B; Hernandez M; Hernandez C; Rodriguez-Moreno JF; Garcia-Donas J
Clin Transl Oncol; 2016 Jan; 18(1):1-8. PubMed ID: 26169213
[TBL] [Abstract][Full Text] [Related]
2. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
[TBL] [Abstract][Full Text] [Related]
3. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.
Rodríguez-Antona C; García-Donas J
Pharmacogenomics; 2012 Nov; 13(14):1621-33. PubMed ID: 23148638
[TBL] [Abstract][Full Text] [Related]
4. Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer.
Pompas-Veganzones N; Sandonis V; Perez-Lanzac A; Beltran M; Beardo P; Juárez A; Vazquez F; Cozar JM; Alvarez-Ossorio JL; Sanchez-Carbayo M
Tumour Biol; 2016 Oct; 37(10):14301-14310. PubMed ID: 27592258
[TBL] [Abstract][Full Text] [Related]
5. [The role of angiogenesis in renal carcinoma].
Bussolati B; Satolli MA; Camussi G
G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
[TBL] [Abstract][Full Text] [Related]
6. Emerging antiangiogenics for renal cancer.
Domblides C; Gross-Goupil M; Quivy A; Ravaud A
Expert Opin Emerg Drugs; 2013 Dec; 18(4):495-511. PubMed ID: 24274612
[TBL] [Abstract][Full Text] [Related]
7. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
8. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents.
Choueiri TK
Clin Genitourin Cancer; 2008 Mar; 6(1):15-20. PubMed ID: 18501077
[TBL] [Abstract][Full Text] [Related]
10. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
12. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Khella HWZ; Butz H; Ding Q; Rotondo F; Evans KR; Kupchak P; Dharsee M; Latif A; Pasic MD; Lianidou E; Bjarnason GA; Yousef GM
Mol Ther; 2015 Nov; 23(11):1748-1758. PubMed ID: 26201448
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series.
Zustovich F; Ferro A; Farina P
Clin Genitourin Cancer; 2014 Jun; 12(3):e107-10. PubMed ID: 24583162
[No Abstract] [Full Text] [Related]
14. Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
Niinivirta M; Enblad G; Edqvist PH; Pontén F; Dragomir A; Ullenhag GJ
J Cancer Res Clin Oncol; 2017 Jun; 143(6):961-970. PubMed ID: 28260162
[TBL] [Abstract][Full Text] [Related]
15. Perspective: What next for treatment?
Motzer RJ
Nature; 2016 Sep; 537(7620):S111. PubMed ID: 27626781
[No Abstract] [Full Text] [Related]
16. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
17. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
